Xiao-I Corporation Provides Further Update on Shanghai Xiao-I’s Patent Infringement Lawsuit Against Apple
SHANGHAI, March 31, 2026 /PRNewswire/ — Xiao-I Corporation (NASDAQ: AIXI), a leading developer of AI solutions, today provides an additional material update... Read more.
Vantage Bank adopts Finzly’s newly launched FX STAR+ application, running on the BankOS platform
Finzly unifies Vantage’s domestic wires and FX operations, providing smarter, faster and better client service. CHARLOTTE, N.C., March 31, 2026 /PRNewswire/... Read more.
EarthEcho International and SC Johnson Partner for Third Year to Mobilize Future Generations with Solutions for Tackling Plastic Waste
The Marine Plastics Ambassadors program focuses on providing participants with advocacy training and policy engagement opportunities. WASHINGTON, March 31, 2026... Read more.
Vantage Bank adopts Finzly’s newly launched FX STAR+ application, running on the BankOS platform
Finzly unifies Vantage’s domestic wires and FX operations, providing smarter, faster and better client service. CHARLOTTE, N.C., March 31, 2026 /PRNewswire/... Read more.
EarthEcho International and SC Johnson Partner for Third Year to Mobilize Future Generations with Solutions for Tackling Plastic Waste
The Marine Plastics Ambassadors program focuses on providing participants with advocacy training and policy engagement opportunities. WASHINGTON, March 31, 2026... Read more.
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated,... Read more.
EarthEcho International and SC Johnson Partner for Third Year to Mobilize Future Generations with Solutions for Tackling Plastic Waste
The Marine Plastics Ambassadors program focuses on providing participants with advocacy training and policy engagement opportunities. WASHINGTON, March 31, 2026... Read more.
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated,... Read more.
ABK Biomedical and MURR Forge Long-Term Partnership to Advance Breakthrough Cancer Therapy
HALIFAX, NS, March 31, 2026 /PRNewswire/ – ABK Biomedical and the University of Missouri Research Reactor (MURR) are powering the next generation of cancer... Read more.
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated,... Read more.